AUM Biosciences merges with Nasdaq listed Mountain Crest
indiatimes.com
science
2022-10-20 15:30:00

AUM Biosciences, a clinical-stage biotechnology company based in Singapore, promoted by non-resident Indian (NRI) entrepreneur Vivek Doshi, on Thursday said it is going public through a merger with Mountain Crest, a US-based Nasdaq listed special purpose acquisition company. The transaction is expected to close in the first quarter of 2023, reflects a pre-money valuation of $400 million for AUM Biosciences and will see around $69 million in gross proceeds. The merged companies will operate under a new entity called Holdco.
